Related Experiment Video
Updated: May 5, 2026
Intracranial Injection of Adeno-associated Viral Vectors
Published on: November 17, 2010
Toxicity and Biodistribution of the Oncolytic Virus VCN-01 Following Intracranial Injection in Syrian Hamsters
Daniel Palacios-Alonso1,2,3, Miriam Bazan-Peregrino4, Marta Zalacain1,2,3
1Department of Pediatrics, Clinica Universidad de Navarra, Pamplona, Spain.
Abstract:
Among solid pediatric tumors, brain tumors are the leading cause of cancer-related mortality. While survival rates have improved for certain pediatric brain tumor subtypes, the overall prognosis remains poor. Consequently, there is an urgent need for novel therapies that are not only effective but also less toxic. Oncolytic viruses have emerged as promising therapeutic agents due to their ability to selectively replicate in tumor cells while sparing healthy tissue and their potential to induce systemic antitumor immune responses. VCN-01 is a replication-competent oncolytic adenovirus whose efficacy has been demonstrated in clinical trials after systemic administration in combination with chemotherapy. Evidence of antitumor activity has also been obtained after intracranial administration in preclinical models of various brain tumors, including high-grade gliomas. However, before progressing to clinical trials for those indications, it is essential to assess the safety of its intracranial administration. In this study, we evaluated the toxicity and biodistribution of VCN-01 following intracranial injection in a Syrian hamster model. Two viral doses were tested: 1.5 × 109 and 1.5 × 1010 viral particles (vp)/animal, corresponding to 5 and 50 times the starting clinical dose (1010 vp/patient), respectively. Our toxicity analysis revealed a favorable safety profile, with no adverse effects observed following administration. Biodistribution studies demonstrated that VCN-01 primarily remained confined to the brain, with only minimal presence detected in peripheral tissues. The neutralizing antibody response against the virus was stronger in females than in males, correlating with a lower detection of vp in females compared with males. In conclusion, these findings support the safety of intracranial administration of VCN-01 and provide a strong rationale for its further development as a therapeutic option for patients with brain tumors.
Insights
Intracranial administration of VCN-01, an oncolytic adenovirus, shows a favorable safety profile in a preclinical brain tumor model. Biodistribution studies confirm VCN-01 remains confined to the brain, supporting its potential for treating pediatric brain tumors.
Area of Science:
- Oncology
- Virology
- Gene Therapy
Background:
- Pediatric brain tumors are a leading cause of cancer mortality, necessitating novel, less toxic therapies.
- Oncolytic viruses, like VCN-01, offer selective tumor cell replication and potential immune stimulation.
- VCN-01 has shown efficacy systemically and antitumor activity intracranially in preclinical models.
Purpose of the Study:
- To evaluate the safety and biodistribution of VCN-01 after intracranial administration in a Syrian hamster model.
- To establish a preclinical safety profile for VCN-01 prior to human clinical trials for brain tumors.
Main Methods:
- Intracranial injection of VCN-01 at two doses (1.5 × 109 and 1.5 × 1010 viral particles/animal) in Syrian hamsters.
- Toxicity assessment through observation of adverse effects.
- Biodistribution analysis to track viral particle presence in brain and peripheral tissues.
- Measurement of neutralizing antibody responses.
Main Results:
- VCN-01 demonstrated a favorable safety profile with no observed adverse effects at tested doses.
- Biodistribution studies showed VCN-01 was primarily confined to the brain, with minimal systemic spread.
- Females exhibited a stronger neutralizing antibody response, correlating with lower viral particle detection.
Conclusions:
- Intracranial administration of VCN-01 is safe in a preclinical model.
- VCN-01's confined brain distribution supports its potential as a localized therapy for brain tumors.
- These findings provide a strong rationale for advancing VCN-01 into clinical trials for brain tumor treatment.
